IOL Chemicals Announces ₹495 Crore Expansion Across Ibuprofen, CDMO and Specialty Chemicals
IOL Chemicals and Pharmaceuticals Ltd (NSE: IOLCP) has announced a major expansion and diversification programme involving approximately ₹495 crore of investment across three strategic initiatives: a major increase in Ibuprofen capacity, entry into pharmaceutical formulation CDMO, and a dedicated specialty chemicals manufacturing facility for a global chemical company.
The announcement is significant because it could broaden IOL Chemicals’ revenue base beyond its existing API and specialty-chemicals operations while increasing manufacturing capacity and improving long-term customer visibility.
IOL Chemicals to Increase Ibuprofen Capacity by 6,000 MT
The company is setting up a new fully backward-integrated Ibuprofen manufacturing unit at its existing facility in Barnala, Punjab.
The new unit will have an installed capacity of 6,000 MT per annum.
IOL Chemicals currently has Ibuprofen capacity of 12,000 MTPA, with capacity utilisation at around 95%. Once the new facility is commissioned, total Ibuprofen capacity will rise to 18,000 MTPA.
The estimated investment for the expansion is approximately ₹350 crore, which will be funded entirely through internal accruals.
Commercialisation is expected by December 2027.
Why the Ibuprofen expansion matters
The company said the expansion is being undertaken to address growing global demand for Ibuprofen and strengthen its position as a leading global manufacturer.
The additional capacity is also supported by ongoing business development and customer engagements across international markets.
Importantly, the new facility will remain backward integrated, which is an existing competitive strength of IOL Chemicals.
Higher capacity could allow the company to:
- Meet increasing international customer demand
- Improve supply reliability
- Strengthen its position in the global Ibuprofen market
- Capture additional volumes from existing and new customers
- Support long-term growth in its pharmaceutical business
The current utilisation of around 95% also indicates that the existing Ibuprofen capacity is operating at a relatively high level, making the planned expansion more meaningful than a purely speculative capacity announcement.
IOL Chemicals Enters Pharmaceutical CDMO Business
In another important development, IOL Chemicals has entered the Contract Development and Manufacturing Organisation (CDMO) business for pharmaceutical formulations.
The company has installed a new formulation manufacturing facility at its existing Barnala site with an installed capacity of approximately:
1,500 million tablets per annum, or equivalent volume of Direct Compressible Grade.
The facility was established at an estimated project cost of approximately ₹110 crore, again funded entirely through internal accruals.
The company expects to commercialise the facility during Q3 FY2027.
European customers are the initial focus
The new CDMO facility has been established primarily to meet the long-term contract manufacturing requirements of the company’s anchor customers in Europe.
This is an important aspect of the announcement because the initiative is described as a customer-led expansion, rather than simply building capacity first and looking for customers later.
IOL Chemicals intends to leverage its existing:
- Manufacturing capabilities
- Quality standards
- Regulatory compliance
- Technical expertise
- Existing customer relationships
The company has also completed the required regulatory inspection and received a GMP Certificate from the National Centre for Public Health and Pharmacy, Directorate for Drug Inspection, Hungary.
This regulatory clearance is an important milestone ahead of commercialisation.
New Specialty Chemicals Facility Under Long-Term Tolling Arrangement
The third initiative involves setting up a dedicated specialty chemicals manufacturing facility for a leading global chemical company.
The facility will be developed under a long-term tolling arrangement.
IOL Chemicals plans to invest approximately ₹35 crore in the facility, funded through internal accruals.
Commercialisation is expected during Q3 FY2027.
The company will manufacture and supply the specialty chemical product exclusively for the customer under agreed contractual terms.
The identity of the customer and detailed commercial terms have not been disclosed because of confidentiality obligations.
However, IOL Chemicals stated that the arrangement is expected to contribute materially to its revenue stream once commercial supplies begin.
Why the tolling arrangement is important
Unlike a conventional capacity expansion where future demand may be uncertain, a dedicated facility under a long-term customer arrangement provides greater visibility over future utilisation.
The company expects the arrangement to:
- Provide stable long-term demand
- Strengthen manufacturing capabilities
- Expand its specialty chemicals presence
- Increase exposure to contract manufacturing
- Support sustainable long-term growth
The company also confirmed that the customer is not a related party.
Total Investment of Around ₹495 Crore
Taken together, the three initiatives represent approximately ₹495 crore of investment:
- ₹350 crore — Ibuprofen capacity expansion
- ₹110 crore — Pharmaceutical formulation CDMO facility
- ₹35 crore — Dedicated specialty chemicals facility
All three projects are being funded through internal accruals.
This is important from an investor perspective because the company is not relying on fresh equity issuance or substantial external borrowing for these initiatives.
At the same time, investors should monitor how much of the company’s internal cash generation is absorbed by these projects and whether the investments translate into higher utilisation, revenue and margins over the next few years.
What Could Change for IOL Chemicals?
The announcement potentially changes the company’s growth profile in three ways.
1. Higher Ibuprofen volumes
Ibuprofen capacity will increase from 12,000 MTPA to 18,000 MTPA, representing a 50% increase in installed capacity.
2. Entry into pharmaceutical CDMO
The company is moving further down the pharmaceutical value chain by adding formulation manufacturing capabilities instead of remaining primarily focused on APIs.
3. Greater specialty-chemicals visibility
The dedicated facility under a long-term tolling arrangement could provide better revenue visibility once commercial production begins.
Together, these initiatives could make IOL Chemicals’ business mix more diversified.
Stock Market Reaction
The announcement comes after a strong rally in IOL Chemicals shares.
The stock had closed at around ₹210.98 on September 8, after touching a 52-week high of approximately ₹219.05. It had gained substantially over the preceding months.
On September 9, the stock was trading around ₹209–₹210 during the session despite the expansion announcement, suggesting that investors were not immediately chasing the stock higher amid the broader market sell-off.
Therefore, investors should distinguish between the fundamental significance of the announcement and the short-term share-price reaction.
What Investors Should Watch
The expansion story is positive, but the benefits will be realised over time.
Investors should track:
- Progress of the 6,000-MTPA Ibuprofen project
- Commercialisation by December 2027
- Utilisation of the new Ibuprofen capacity
- CDMO customer additions and order visibility
- Commercialisation of the formulation facility in Q3 FY2027
- Revenue contribution from the European CDMO business
- Execution of the specialty-chemicals tolling arrangement
- Margins and return on capital from the ₹495 crore investment programme
- Whether internal accruals remain sufficient to fund the expansion without materially increasing leverage
Investor Takeaway
IOL Chemicals’ September 9 announcement is a meaningful strategic expansion rather than a routine corporate disclosure.
The ₹350 crore Ibuprofen expansion addresses capacity constraints and growing global demand, while the ₹110 crore pharmaceutical CDMO facility provides the company with a new growth avenue focused initially on European customers.
The ₹35 crore specialty-chemicals facility is particularly interesting from a revenue-visibility perspective because it is being established for a leading global chemical company under a long-term tolling arrangement.
With approximately ₹495 crore of investment across three initiatives, IOL Chemicals is effectively pursuing a combination of capacity expansion, business diversification and customer-led manufacturing.
The key question for investors will now be whether these investments translate into sustained revenue growth, higher capacity utilisation and improved profitability as the facilities are commercialised during FY2027 and FY2028.
For investors, IOL Chemicals is now worth tracking for its Ibuprofen expansion, pharmaceutical CDMO entry and long-term specialty-chemicals opportunity.